Preventive Effects of Low-dose Aspirin as Adjuvant Therapy After Radical Nephrectomy on Disease Recurrence/Metastasis and Survival in Patients With Locally Advanced Renal Cell Carcinoma: an Observational Prospective Cohort Study
Condition: Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma
Study Type: Observational
Clinical Trials Identifier NCT 8-digits: NCT03734614
Sponsor: RenJi Hospital
- Age: minimum 18 Years maximum N/A
- Gender: All
- Patients must complete radical surgery more than 4 weeks and less than 12 weeks prior to study entry
- Patients must have histologically or cytologically confirmed renal cell carcinoma. Using 2017 (American Joint Committee on Cancer [AJCC] 8th edition) TNM Staging, patients must be one of the following:
- pT2aG3 or G4N0M0
- Patients must have no clinical or imaging evidence of visible residual lesions or distant metastases (M0) after nephrectomy
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Patients must be able to swallow pills
- Patients with haemorrhagic diathesis (i.e. haemophilia).
- Patients with prior malignant tumors except for kidney cancers in the past 5 years.
- Patients with documented or suspected metastases.
- Patients with serious, nonhealing wound, ulcer, or bone fracture.
- Patients with a history of stroke, coronary arterial disease, angina, or vascular disease.
- Patients who are pregnant, lactating, or not using adequate contraception.
- Patients who have known allergy to NSAID or Aspirin.
- Patients receiving other antiplatelet agents (i.e. clopidogrel, ticlopidine) or anticoagulants (i.e. warfarin, low molecular weight heparins).
- Patients receiving current long term treatment (≥1 month) with Aspirin or other NSAIDs.
- Subject unwilling or unable to comply with study requirements.
View trial on ClinicalTrials.gov